Health Care·Pharmaceuticals·$2.2B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.46 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.46 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Tone: Neutral
Management acknowledged the challenges faced during the quarter but emphasized their commitment to growth. They did not provide specific guidance for future performance.
Management did not provide specific revenue figures or guidance for the upcoming quarters.
The company remains focused on its long-term strategic goals.
Phibro Animal Health's earnings report showed stable EPS but lacked revenue details, leading to a slight decline in stock price by 0.82%. The absence of guidance may leave investors uncertain about the company's future performance. Overall, the market reaction reflects cautious sentiment among investors.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
IDEXX LABS INC
May 4, 2018